| abstract |
The present invention relates to a pharmaceutical composition for treating and preventing degenerative neurological diseases containing cilostazol or a pharmacologically acceptable salt thereof as an active ingredient. Said cilostazol or pharmacologically acceptable salt thereof is already commercially available for other uses, while DNA binding of NK-κB and neuronal damage models by proinflammatory and neurotoxin factors that activate microglia by LPS and By inhibiting transcriptional activity and blocking the up signal of NK-κB activation by inhibiting ERK 1/2 and JNK without affecting the activity of p38 MAPK, NO, PGE 2 , It inhibits IL-1β, TNF-α, and MCP-1 in a concentration-dependent manner, thereby inhibiting pro-inflammatory mediators and cytokine production in activated microglia, which can be useful as drugs or foods for the treatment or prevention of neurodegenerative diseases. . |